Cholangiocarcinomas Recruiting Phase 2 Trials for Ceritinib (DB09063)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02374489A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar CholangiocarcinomaTreatment
NCT02638909Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesTreatment